Fc glycans of therapeutic antibodies as critical quality attributes - Test2 - elhamkhani - TriplyDB

Fc glycans of therapeutic antibodies as critical quality attributes

Fc glycans of therapeutic antibodies as critical quality attributes

http://www.wikidata.org/entity/Q26799266

about

Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications Enzymes for N-Glycan Branching and Their Genetic and Nongenetic Regulation in Cancer Posttranslational Modifications and the Immunogenicity of Biotherapeutics Fc gamma receptors: glycobiology and therapeutic prospects Glycan analysis of therapeutic glycoproteins Data Independent Analysis of IgG Glycoforms in Samples of Unfractionated Human Plasma.Exploring Site-Specific N-Glycosylation of HEK293 and Plant-Produced Human IgA Isotypes.Ultrafast and high-throughput N-glycan analysis for monoclonal antibodies.Human plasma protein N-glycosylation Efficient Production of a Bioactive Bevacizumab Monoclonal Antibody Using the 2A Self-cleavage Peptide in Transgenic Rice Callus.Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells Physicochemical and Biological Characterization of the Proposed Biosimilar Tocilizumab.Statistical characterization of therapeutic protein modifications.Granulocyte colony-stimulating factor (GCSF) fused with Fc Domain produced from E. coli is less effective than Polyethylene Glycol-conjugated GCSF.Glycosylation profile and biological activity of Remicade® compared with Flixabi® and Remsima®.Impact of IgG Fc-Oligosaccharides on Recombinant Monoclonal Antibody Structure, Stability, Safety, and Efficacy.Biological roles of glycans.Modulating carbohydrate-protein interactions through glycoengineering of monoclonal antibodies to impact cancer physiology.Quantitative glycomics using liquid phase separations coupled to mass spectrometry.Characterization of isomeric glycan structures by LC-MS/MS.Transient Glyco-Engineering to Produce Recombinant IgA1 with Defined N- and O-Glycans in Plants Automated N-Glycosylation Sequencing Of Biopharmaceuticals By Capillary Electrophoresis.Reduced paucimannosidic N-glycan formation by suppression of a specific β-hexosaminidase from Nicotiana benthamiana.Pharmacokinetics of Monoclonal Antibodies.A Quadrupole Dalton-based multi-attribute method for product characterization, process development, and quality control of therapeutic proteins.Crystallizable Fragment Glycoengineering for Therapeutic Antibodies Development.Designing a mutant Candida uricase with improved polymerization state and enzymatic activity.Plant-expressed Fc-fusion protein tetravalent dengue vaccine with inherent adjuvant properties.Structural characterization of the Man5 glycoform of human IgG3 Fc.Beyond binding: antibody effector functions in infectious diseases.N-Glycosylation of an IgG antibody secreted by Nicotiana tabacum BY-2 cells can be modulated through co-expression of human β-1,4-galactosyltransferase.Implementation of Glycan Remodeling to Plant-Made Therapeutic Antibodies.Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review.Engineering an IgG Scaffold Lacking Effector Function with Optimized Developability.Assessment of structural and functional similarity of biosimilar products: Rituximab as a case study.The process defines the product: what really matters in biosimilar design and production?A novel bicistronic gene design couples stable cell line selection with a fucose switch in a designer CHO host to produce native and afucosylated glycoform antibodies.Genome-Wide Association Study on Immunoglobulin G Glycosylation Patterns.An oligosaccharyltransferase from Leishmania major increases the N-glycan occupancy on recombinant glycoproteins produced in Nicotiana benthamiana.Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab.

P2860

Q26738810-0B28F5E4-4E04-4A07-B1F0-49C6A27694AD Q26748089-6E0ED0B7-E306-4D33-B87C-234B6E35C881 Q26748614-2C26C02F-5B09-4772-BEF0-99536F7CA5EB Q28076303-C818A39B-EC5E-4851-A393-69A2D3D7FBFA Q28082842-4E1C5F50-4C8F-4CFD-BF53-E2E8D36B7524 Q31131930-9C2A0BC5-F0E3-423D-B728-5DE66A03C0F1 Q33891585-C5D6724B-25AC-4A68-92D5-5A96A385B2B4 Q35990992-C9135D22-909A-4D0A-9E37-69BA4759F061 Q36963945-F2C918F2-351C-4424-912E-D8EF9234E0B7 Q37159302-CF8988A5-6145-4B34-A7B7-B7151E05FAF8 Q37589825-7AE9E95B-11A3-4FF9-BF75-34C3046A74C9 Q37703405-6AA3DE65-4BBA-44F9-8683-898913228090 Q38628116-7764942B-0C9B-4C5C-84FB-7A64F4E46683 Q38696361-97F943E0-F99E-4CC1-B2BF-E8E28DFCAAF1 Q38699354-0C22BE95-D10D-4CA8-9F15-59D791F6C39B Q38762019-ECB8AB3A-FE7E-4DFF-B8C1-07732526A690 Q38936714-B9B4B2C2-A48C-4597-AED3-5FB8C969CA0D Q38957458-5694B746-C5C6-4EE5-AECF-C29299EDB93A Q39124498-DA68B171-E8CD-4C89-9F97-E1C516B14644 Q39215799-86D751F4-3D91-4DAB-B8FE-6684A9CE4D69 Q40011916-D8EA36D3-5220-45CC-806E-3482A649808B Q41718512-9E0ADBF0-0DF0-4248-B6D5-68F52ADDAE0A Q42105653-CD5AA133-6DEC-4D3A-94F5-1418CA1AA701 Q42118646-32DA8C48-D25C-4099-ACF9-00615B97468E Q42280824-E7EE0BF7-5C69-496E-9A58-DE49C906F280 Q44852748-20BEA463-2C66-4AA2-A02C-627E78F26D56 Q46257023-2759A331-5A29-4958-869D-E8646F368EBC Q47265866-AA24FC09-8129-42B1-B5CA-2EC8BD175245 Q47445247-47D5CE62-B433-4404-9F07-CEE1EE9B5CE5 Q47602559-92AAE97B-86FE-4094-A981-CDD6B3E35D35 Q48089742-548D488F-C874-4054-AFBD-7C4D22D7E99D Q48134110-ADBE6E3E-6807-4398-A260-D0587DF1D7AF Q49979586-57F23A23-2023-4684-9A8F-F49963782A9D Q50048248-5DA56143-3B27-4ED9-BD8E-806E7035CAD3 Q50098437-C4CF7479-CF19-4956-8211-6884CA60C368 Q50115805-12BA9165-F292-45B0-AE97-A6ADE6328D31 Q50199955-A0B8DFEF-47F1-4C01-A723-F1D6206621C0 Q51763368-9FC732E3-8671-4E2F-BE5E-C19F7D6E6E04 Q52373100-2C8E36CE-FDA9-4D71-9595-F4CF5D86A9D2 Q52648922-B916BDB5-4EA2-43B1-A688-C400B0DC0F6F

P2860

Fc glycans of therapeutic antibodies as critical quality attributes

http://www.wikidata.org/entity/Q26799266

description

2015 nî lūn-bûn

@nan

2015 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Fc glycans of therapeutic antibodies as critical quality attributes

@ast

Fc glycans of therapeutic antibodies as critical quality attributes

@en

Fc glycans of therapeutic antibodies as critical quality attributes

@nl

type

label

Fc glycans of therapeutic antibodies as critical quality attributes

@ast

Fc glycans of therapeutic antibodies as critical quality attributes

@en

Fc glycans of therapeutic antibodies as critical quality attributes

@nl

prefLabel

Fc glycans of therapeutic antibodies as critical quality attributes

@ast

Fc glycans of therapeutic antibodies as critical quality attributes

@en

Fc glycans of therapeutic antibodies as critical quality attributes

@nl

P1433

Q26799266-578A188B-D10F-42EA-8924-D510FBB17836

P1476

Q26799266-C24BEE55-83D4-47D7-8760-19E89D4FF3CD

P2093

Q26799266-1FDD6C33-5BBA-4132-AAF3-2F275CD41627

Q26799266-5424017E-4D58-4526-BC15-2A2D979F72AC

P275

Q26799266-30E46011-2E99-418B-95AF-0112FB425B29

P2860

Q26799266-0243B598-721C-4F0D-B08F-38F299C916B7

Q26799266-029E97BF-5A12-4689-9C18-9C3EC6538A10

Q26799266-03F73EFE-3D84-4E04-BD44-05AD25674829

Q26799266-050965CF-132C-4AB6-9EEB-A2400F9D08E2

Q26799266-062FF56A-2E4C-470F-9C40-08F78D0A8AA5

Q26799266-087D3D86-A315-4545-8EE8-479951AECBEA

Q26799266-125FE0D4-E3C1-473A-955E-FF45FC1C6DD7

Q26799266-1A05DC2B-6FB7-45A2-A027-08BA62D8E106

Q26799266-1B5DA4CD-7848-4E61-A905-9297FEE16EE0

Q26799266-208F6F02-2AB9-4C1C-888C-15D43D7E64D9

P304

Q26799266-B6F63B0C-CBD5-458A-8229-E4B633E095E4

P31

Q26799266-107019E1-C74D-4516-AED4-5DE2BA06555B

Q26799266-BCCE2838-2029-4C22-87AA-498B902117F8

P3181

Q26799266-977A219D-7976-4494-A45E-FE7AF85E09AF

P356

Q26799266-A57DBECA-5517-4F52-B50E-5D638A1C43F1

P407

Q26799266-0DE1CC4B-929E-4D75-AA23-96824D7C88D3

P433

Q26799266-9A5B6BDF-15C0-4ADA-891B-FD9161972EFC

P478

Q26799266-B256A6E7-A3AC-4E93-BD39-2E96BD6CC34A

P577

Q26799266-063B19BE-08B0-4A15-903E-C274E5CB28E9

Q26799266-FD55968E-C181-4998-97D3-A9906EC9A42A

P5875

Q26799266-FDCD5B36-B807-4670-977B-9BBE0E310B52

P698

Q26799266-0B94E032-8CF3-4B63-ABCD-D929A65962AE

P921

Q26799266-04E86215-5577-4F7B-938F-FF373BF25BC1

Q26799266-161ABC03-CEDF-4938-8857-991000FD8B66

Q26799266-3635D597-F62C-4FF4-8638-DC83A8C5F55B

Q26799266-41FD2CB8-6F69-44F0-AEEE-009EF00345A9

Q26799266-436B760B-F47F-4C48-B642-14EBD2F8BAFC

Q26799266-A46C075D-87A9-4152-B9A3-788997CCD61B

Q26799266-B19A18C8-3BDB-43D6-B03A-31F483C8D79F

P932

Q26799266-E94F443B-8D47-411A-8BC3-FC81F326C517

P3181

P356

P1433

P1476

Fc glycans of therapeutic antibodies as critical quality attributes

@en

P2093

Dietmar Reusch

http://www.w3.org/2001/XMLSchema#string

Max L Tejada

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid

Molecular basis for immune complex recognition: a comparison of Fc-receptor structures

Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1

Chemical and Structural Analysis of an Antibody Folding Intermediate Trapped during Glycan Biosynthesis

Stimulatory and inhibitory signals originating from the macrophage Fcgamma receptors

Mannose receptor-mediated regulation of serum glycoprotein homeostasis

Anti-inflammatory actions of intravenous immunoglobulin

Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells

Fcgamma receptors: old friends and new family members

In vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activity

P304

1325-34

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

418504

http://www.w3.org/2001/XMLSchema#string

P356

10.1093/GLYCOB/CWV065

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2015-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

280998644

http://www.w3.org/2001/XMLSchema#string

P698

26263923

http://www.w3.org/2001/XMLSchema#string

P921

Angliavandeniai

monoclonal antibody

preventive health services

biomedical investigative technique

P932

4634315

http://www.w3.org/2001/XMLSchema#string